These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 9307656)
1. Evidence that certain 8-aminoquinolines are potentially effective drugs against Chagas disease. Kinnamon KE; Poon BT; Hanson WL; Waits VB Ann Trop Med Parasitol; 1997 Mar; 91(2):147-52. PubMed ID: 9307656 [TBL] [Abstract][Full Text] [Related]
2. Primaquine analogues that are potent anti-Trypanosoma cruzi agents in a mouse model. Kinnamon KE; Poon BT; Hanson WL; Waits VB Ann Trop Med Parasitol; 1996 Oct; 90(5):467-74. PubMed ID: 8915122 [TBL] [Abstract][Full Text] [Related]
3. In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model. Kinnamon KE; Steck EA; Hanson WL; Chapman WL J Med Chem; 1977 Jun; 20(6):741-4. PubMed ID: 69024 [TBL] [Abstract][Full Text] [Related]
4. The activity against Trypanosoma cruzi and cutaneous leishmaniasis, and toxicity, of moxipraquine (349C59). Beveridge E; Caldwell IC; Latter VS; Neal RA; Udall V; Waldron MM Trans R Soc Trop Med Hyg; 1980; 74(1):43-51. PubMed ID: 6776663 [TBL] [Abstract][Full Text] [Related]
5. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection. Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038 [TBL] [Abstract][Full Text] [Related]
6. [Nifurtimox as a prophylactic drug to prevent reactivation in chronic chagasic patients treated with corticoid for associated diseases]. Rassi A; Neto VA; de Siqueira AF; Leite MS Rev Soc Bras Med Trop; 1998; 31(3):249-55. PubMed ID: 9612015 [TBL] [Abstract][Full Text] [Related]
7. Etiological treatment for infection by Trypanosoma cruzi. Amato Neto V Rev Inst Med Trop Sao Paulo; 1999; 41(4):211-3. PubMed ID: 10564912 [No Abstract] [Full Text] [Related]
8. Chagas' disease: a search for treatment and a question--should the disease be of military concern? Kinnamon KE; Poon BT; Scovill JP; Hanson WL; Waits VB Mil Med; 1997 Aug; 162(8):527-32. PubMed ID: 9271903 [TBL] [Abstract][Full Text] [Related]
9. Activity of anticancer compounds against Trypanosoma cruzi-infected mice. Kinnamon KE; Poon BT; Hanson WL; Waits VB Am J Trop Med Hyg; 1998 Jun; 58(6):804-6. PubMed ID: 9660468 [TBL] [Abstract][Full Text] [Related]
10. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study. Mazzeti AL; Diniz LF; Gonçalves KR; Nascimento AFS; Spósito PAF; Mosqueira VCF; Machado-Coelho GLL; Ribeiro I; Bahia MT Biochem Pharmacol; 2018 Feb; 148():213-221. PubMed ID: 29309767 [TBL] [Abstract][Full Text] [Related]
11. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies. Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678 [TBL] [Abstract][Full Text] [Related]
12. [Nifurtimox treatment of chronic Chagasic infection in children]. Schenone H; Contreras M; Solari A; García A; Rojas A; Lorca M Rev Med Chil; 2003 Sep; 131(9):1089-90. PubMed ID: 14635599 [No Abstract] [Full Text] [Related]
13. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy]. Gallerano RR; Sosa RR Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232 [TBL] [Abstract][Full Text] [Related]
14. Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model. Valle-Reyes JS; Melnikov V; Dobrovinskaya O; Rodriguez-Hernández A; Wookee-Zea C; Pimientel-Rodrigez V; Rueda-Valdovinos G; Delgado-Enciso I; López-Lemus UA; Espinoza-Gómez F Exp Parasitol; 2017 Jan; 172():44-50. PubMed ID: 28011170 [TBL] [Abstract][Full Text] [Related]
15. Searching for new drugs for Chagas diseases: triazole analogs display high in vitro activity against Trypanosoma cruzi and low toxicity toward mammalian cells. Faria RX; Gonzaga DTG; Pacheco PAF; Souza ALA; Ferreira VF; da Silva FC J Bioenerg Biomembr; 2018 Apr; 50(2):81-91. PubMed ID: 29473131 [TBL] [Abstract][Full Text] [Related]
16. Effect of length of treatment with Bayer 2502 on isolation of Trypanosoma cruzi and resistance to challenge in the mouse. Morrow DT; Wescott RB; Davis WC Am J Trop Med Hyg; 1977 May; 26(3):382-6. PubMed ID: 405877 [TBL] [Abstract][Full Text] [Related]
17. In pursuit of drugs for American trypanosomiasis: evaluation of some "standards" in a mouse model. Kinnamon KE; Poon BT; Hanson WL; Waits VB Proc Soc Exp Biol Med; 1997 Dec; 216(3):424-8. PubMed ID: 9402149 [TBL] [Abstract][Full Text] [Related]
18. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Filardi LS; Brener Z Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683 [TBL] [Abstract][Full Text] [Related]
19. The in vivo trypanocidal effect of the diterpene 5-epi-icetexone obtained from Salvia gilliesii. Lozano E; Strauss M; Spina R; Cifuente D; Tonn C; Rivarola HW; Sosa MA Parasitol Int; 2016 Feb; 65(1):23-26. PubMed ID: 26341064 [TBL] [Abstract][Full Text] [Related]
20. Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015). Rodriguez JB; Falcone BN; Szajnman SH Expert Opin Ther Pat; 2016 Sep; 26(9):993-1015. PubMed ID: 27376456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]